Filter Results
:
(599)
Show Results For
-
All HBS Web
(1,023)
- People (4)
- News (249)
- Research (599)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
Show Results For
-
All HBS Web
(1,023)
- People (4)
- News (249)
- Research (599)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
Sort by
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and...
View Details
Keywords:
Health Care and Treatment;
Strategic Planning;
Competition;
Patents;
Innovation and Invention;
Pharmaceutical Industry;
Biotechnology Industry;
United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
- Research Summary
Physician vs. Patient Incentives in Prescription Drug Choice
The market for medical care involves interactions among patients, providers, and the insurers who pay for the care of their enrollees. The division of responsibilities creates scope for agency costs and moral hazard in the physician's treatment choice....
View Details
- September 2019 (Revised October 2019)
- Case
Aura Biosciences: Bringing a Breakthrough Drug to Market
By: Robert J. Dolan and Navid Mojir
Dolan, Robert J., and Navid Mojir. "Aura Biosciences: Bringing a Breakthrough Drug to Market." Harvard Business School Case 520-032, September 2019. (Revised October 2019.)
- February 2006 (Revised August 2006)
- Case
deCODE Genetics: Hunting for Genes to Develop Drugs
By: Debora L. Spar
In 1996, Kari Stefansson launched a new kind of biotechnology company and a whole new way of attacking diseases. Based in Iceland, his firm, deCODE Genetics, plans to identify the individual genetic markers that lead to society's most prevalent diseases. To do so, it...
View Details
Keywords:
Information;
Innovation Strategy;
Genetics;
Ethics;
Health Disorders;
Biotechnology Industry;
Iceland
Spar, Debora L., and Chris Bebenek. "deCODE Genetics: Hunting for Genes to Develop Drugs." Harvard Business School Case 706-040, February 2006. (Revised August 2006.)
- June 2001
- Supplement
Merck & Company: Evaluating a Drug Licensing Opportunity
Spreadsheet to (9-201-023). Download only.
View Details
- December 19, 2018
- Article
It's Time to Reform the Orphan Drug Act
By: Nicholas Bagley, Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
Bagley, Nicholas, Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern. "It's Time to Reform the Orphan Drug Act." NEJM Catalyst (December 19, 2018).
- 1996
- Chapter
Eli Lilly and Company: Drug Development Strategy
By: S. Thomke, A. Nimgade and P. Pospisil
- October 2000 (Revised March 2003)
- Case
Merck & Company: Evaluating a Drug Licensing Opportunity
By: Richard S. Ruback and David B Krieger
This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of...
View Details
Keywords:
Decision Making;
Cost vs Benefits;
Opportunities;
Valuation;
Outcome or Result;
Pharmaceutical Industry
Ruback, Richard S., and David B Krieger. "Merck & Company: Evaluating a Drug Licensing Opportunity." Harvard Business School Case 201-023, October 2000. (Revised March 2003.)
- 28 Mar 2023
- Research & Ideas
The FDA’s Speedy Drug Approvals Are Safe: A Win-Win for Patients and Pharma Innovation
Early in the COVID-19 pandemic, the US Food and Drug Administration faced the task of convincing a skeptical public of the safety of new vaccines when the agency began authorizing them for emergency use less than a year after the pandemic...
View Details
- November 2018
- Case
Aura Biosciences: Bringing a Breakthrough Drug to Market
By: Robert J. Dolan and Navid Mojir
- Article
Measuring Competence? Exploring Firm Effects in Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
Henderson, Rebecca M., and Ian Cockburn. "Measuring Competence? Exploring Firm Effects in Drug Discovery." Strategic Management Journal 15 (Winter 1994): 63–84. (Winner of Dan and Mary Lou Schendel Best Paper Prize To honor substantial work published in the Strategic Management Journal presented by Strategic Management Society.)
- 11 Sep 2019
- Research & Ideas
Germany May Have the Answer for Reducing Drug Prices
American lawmakers attempting to stem spiraling drug costs might find inspiration in Germany, where the government’s regulatory model has been curbing price growth without thwarting innovation or access, says research from Harvard...
View Details
- December 2009 (Revised April 2010)
- Teaching Note
GlaxoSmithKline: Reorganizing Drug Discovery (TN) (A) and (B)
Teaching Note for [605074] and [605075].
View Details
- 2000
- Chapter
Measuring Competence? Exploring Firm Effects in Drug Discovery
By: Rebecca M. Henderson and Iain Cockburn
Keywords:
Competency and Skills;
Measurement and Metrics;
Research and Development;
Innovation and Invention;
Pharmaceutical Industry
Henderson, Rebecca M., and Iain Cockburn. "Measuring Competence? Exploring Firm Effects in Drug Discovery." Chap. 6 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter. New York: Oxford University Press, 2000.
- December 1997 (Revised September 2002)
- Supplement
Eli Lilly and Company: Drug Development Strategy (B)
By: Stefan H. Thomke and Ashok Nimgade
Supplements the (A) case.
View Details
Thomke, Stefan H., and Ashok Nimgade. "Eli Lilly and Company: Drug Development Strategy (B)." Harvard Business School Supplement 698-026, December 1997. (Revised September 2002.)
- October 1987 (Revised March 1992)
- Supplement
Boston Fights Drugs (B): Converting Research to Action
By: V. Kasturi Rangan and Jennifer Lawrence
Describes the results of the advertising pre-test described in the (A) case. The group must now decide how to implement its findings for maximum impact.
View Details
Rangan, V. Kasturi, and Jennifer Lawrence. "Boston Fights Drugs (B): Converting Research to Action." Harvard Business School Supplement 588-032, October 1987. (Revised March 1992.)
- 2024
- Working Paper
Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency
By: Mosab Hammoudeh, Joshua Lev Krieger and Jiajie Xu
This paper investigates whether moving R&D from incumbents to startups can increase innovation. Using comprehensive drug development data, we examine the outcomes of drug projects licensed from large firms to startups. We find that these projects licensed to startups...
View Details
Keywords:
Product Development;
Innovation and Invention;
Business Startups;
Research and Development;
Performance Efficiency;
Pharmaceutical Industry
Hammoudeh, Mosab, Joshua Lev Krieger, and Jiajie Xu. "Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency." Harvard Business School Working Paper, No. 24-067, March 2024.
- March 2007
- Teaching Note
Amgen Inc.'s Epogen-Commercializing the First Biotech Blockbuster Drug (TN)
Teaching note to 706454.
View Details
- 2004
- Book
Pharmacopolitics: Drug Regulation in the United States and Germany
By: Arthur A. Daemmrich
Keywords:
Health;
Governing Rules, Regulations, and Reforms;
Government and Politics;
United States;
Germany
Daemmrich, Arthur A. Pharmacopolitics: Drug Regulation in the United States and Germany. University of North Carolina Press, 2004. (Winner of Edward Kremers Award of the American Institute of the History of Pharmacy For best book in pharmaco-historical writing published in the previous two years presented by American Institute of the History of Pharmacy.)